clinical trial

May 13, 2016May 13, 2016

FDA Expands Label for Imbruvica (ibrutinib), a Lymphoma Therapy, to Include Improved Survival and Safety

News

The U.S. Food and Drug Administration (FDA) recently approved an expansion to prescribing information for the kinase inhibitor Imbruvica (ibrutinib), based on improved survival, safety, and efficacy data from studies in people with chronic ... Read more

May 3, 2016May 3, 2016

CHMP Supports EU Approval of Obinutuzumab (Gazyvaro) to Treat Follicular Lymphoma

News

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy and then as monotherapy, to treat select patients with follicular lymphoma. The recommendation is as treatment for ... Read more

April 20, 2016April 20, 2016

FDA Approves Breakthrough Therapy Designation for Hodgkin’s Lymphoma Treatment Keytruda

News

The FDA has granted Merck’s anti-PD-1 therapy Keytruda (pembrolizumab), Breakthrough Therapy Designation (BTD) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin’s lymphoma (cHL). The FDA previously granted BTD ... Read more

April 19, 2016April 19, 2016

Clinical Trial of Chi-Med’s B-Cell Lymphoma Drug Is Launched

News

Hutchison China MediTech Limited, generally called Chi-Med, recently announced the initiation of its first-in-human Phase 1 clinical trial of HMPL-689, a drug the company aims to evaluate in B-cell malignancies. The ... Read more

March 16, 2016March 16, 2016

1st Lymphoma Patient, a Doctor, Being Treated with CAR T-cell Therapy in Phase 2 Study

News

The Wilmot Cancer Institute at the University of Rochester has initiated treatment of the first patient enrolled in a clinical trial of CAR T-cell therapy for lymphoma. The therapy has ... Read more

March 3, 2016March 3, 2016

Cutaneous T-cell Lymphoma Phase 1 Clinical Trial of MiR-155 Inhibitor Now Enrolling Patients

News

miRagen Therapeutics, Inc., announced that it has started a Phase 1 clinical trial (NCT02580552) of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155. The trial’s primary ... Read more